Form 4: Akebia Therapeutics Grants Equity to SVP Malabre

Akebia Therapeutics' SVP and Chief Accounting Officer, Richard C. Malabre, received 79,000 restricted stock units and 119,000 stock options, aligning executive incentives with long-term company performance.

Summary

• Richard C. Malabre, SVP, Chief Accounting Officer of Akebia Therapeutics, Inc. (AKBA), was granted equity awards on January 30, 2026.
• The awards include 79,000 restricted stock units (RSUs) with a grant price of $0.00.
• The awards also include 119,000 stock options with an exercise price of $1.41.
• The RSUs will vest one-third on each of the first, second, and third anniversaries of the grant date (January 30, 2026), subject to continued service.
• The stock options will vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal quarterly installments thereafter, subject to continued service.
• Following these transactions, Mr. Malabre beneficially owns 348,914 shares of common stock and 119,000 derivative stock options.
• The grants were made pursuant to the Issuer's 2023 Stock Incentive Plan, as amended.
• Beneficial ownership also includes 1,500 shares purchased on June 30, 2025, and 1,500 shares on December 31, 2025, under the Issuer's Amended and Restated 2014 Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies strong alignment between executive incentives and long-term shareholder value through equity grants with multi-year vesting schedules.

Positives

• The equity grants align the interests of a key executive, Richard C. Malabre, with those of shareholders, promoting long-term value creation.
• The vesting schedules for both RSUs and stock options incentivize continued service and performance over several years.
• The use of the 2023 Stock Incentive Plan demonstrates a structured approach to executive compensation and retention.

Negatives

• The grants do not represent an immediate cash benefit to the executive, as they are subject to vesting conditions.
• The value of the stock options and RSUs is dependent on the future performance of Akebia Therapeutics' stock price, introducing market risk for the executive.

Risks

• The value of the granted equity is subject to the volatility of Akebia Therapeutics' common stock price.
• The reporting person's ability to realize the full value of the awards is contingent upon their continued service with the Issuer through the vesting dates.
• Potential dilution for existing shareholders from the issuance of new shares upon vesting/exercise of these awards.

Future Outlook

The equity grants, with their multi-year vesting schedules, indicate a long-term incentive structure designed to retain key management and align their financial interests with the future growth and performance of Akebia Therapeutics.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units and stock options is a standard practice in the biotechnology and pharmaceutical industry for executive compensation. These equity awards are crucial for attracting, retaining, and motivating senior leadership, particularly in companies like Akebia Therapeutics, where long-term drug development cycles necessitate sustained commitment and performance.

Comparison to Industry Standards

• Equity grants, including RSUs and stock options, are a common component of executive compensation packages across the biotech sector, comparable to practices at companies such as Biogen Inc. or Vertex Pharmaceuticals Inc., which frequently use such incentives to align executive performance with shareholder value.
• The multi-year vesting schedule for both RSUs (three years) and stock options (four years) is consistent with industry benchmarks for executive retention, ensuring a sustained commitment from key personnel.
• The grant price of $0.00 for RSUs is standard for such awards, while the stock option exercise price of $1.41 would typically be set at or above the market price on the grant date, a common practice to ensure options have intrinsic value only if the stock price appreciates.

Stakeholder Impact

• Shareholders: Positive impact due to increased alignment of executive interests with long-term company performance and shareholder value creation.
• Employees: The grants to a senior executive may signal stability and a commitment to retaining key talent within the company.
• Management: Provides long-term incentives and compensation tied to the company's future success.

Next Steps

• Vesting of one-third of restricted stock units on January 30, 2027, January 30, 2028, and January 30, 2029.
• Vesting of 25% of stock options on January 30, 2027, with the remaining 75% vesting in equal quarterly installments thereafter.
• Continued service of Richard C. Malabre with Akebia Therapeutics, Inc. is required for vesting.

Key Dates

Keywords

Akebia Therapeutics, AKBA, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, SVP Chief Accounting Officer, Stock Incentive Plan